A phase III, randomized, open-label, controlled trial to investigate the efficacy and safety of UB-421 monotherapy as substitution for stable antiretroviral therapy in HIV-1 infected adults

Description: n/a

A phase IIIb/IV randomized open-label trial to compare Dolutegravir + pharmaco-enhanced Darunavir versus recommended standard of care antiretroviral regimens in patients with HIV infection who have failed recommended first line therapy

This is a phase IIIB/IV randomised open-label trial to compare dolutegravir + pharmaco-enhanced darunavir versus recommended…

Pharmacokinetics, efficacy, and safety of Rilpivirin in virologic suppressed HIV-infected Thai adolescents

This is an open-label, single arm study that will describe the immunologic and virologic outcomes (HIV…

A randomized, double-blinded, placebo-controlled trial comparing antiretroviral intensification with Maraviroc and Dolutegravir with no intensification or intensification with Dolutegravir alone for the treatment of cognitive impairment in HIV

Description: n/a

Effect of calcium and high-dose vitamin D supplementation on bone mineral density among prenatally HIV-infected children and adolescents (CAL-D)

This study is a multicenter, randomized, open-labeled, phase II clinical trial comparing the effect of a…

Impact of HIV infection on the population genomics of drug-resistant Mycobacterium tuberculosis: insights from macro-evolutionary analyses

This study will investigate the macroevolution of drug-resistant M. tuberculosis.

Continued access to Etravirine (ETR) in treatment experienced HIV-1 infected children and adolescents

The primary objective is to continue the provision of etravirine (ETR) for patients who previously received…

Randomized trial to prevent vascular events in HIV (REPRIEVE)

This is a randomized trial to prevent vascular events in HIV, tests whether a daily dose…

Clinical significance of Hepatitis C Virus infection among end-stage kidney diseases receiving renal replacement therapy

´╗┐This study is a multicenter, cross sectional study that will assess the prevalence of active HCV…

An open-label trial with TMC278 25 mg q.d. in combination with a background regimen containing 2 nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected subjects, who participated in TMC278 clinical trials

The purpose of the study is to provide continued access to TMC278 in HIV-1 infected patients…